Pharvaris (PHVS) exec Lesage sells 48K shares, exercises options

Rhea-AI Filing Summary

Pharvaris N.V. executive Anne Lesage, Chief Early Development, reported a mix of stock option exercises and open-market sales in Pharvaris common stock. Over two days, she exercised 25,400 shares through stock options at exercise prices of $8.05 and $2.59 per share and sold 48,300 shares in open-market transactions under a pre-arranged Rule 10b5-1 trading plan.

Following these transactions, the filing shows Lesage holding 56,450 Pharvaris common shares directly and 133,969 shares indirectly through GrayMatters Consulting B.V., an entity she controls. Remaining stock options include 82,000 options with an $8.05 exercise price and 9,072 options with a $2.59 exercise price.

Insider Trade Summary 10b5-1

Net Seller: 48,300 shares ($1,459,970)

Net Sell 11 txns

Insider Lesage Anne

Role Chief Early Development

Sold 48,300 shs ($1.46M)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	3,700	$0.00	--
Exercise	Stock Option (Right to Buy)	18,000	$0.00	--
Exercise	Common Stock	3,700	$2.59	$10K
Sale	Common Stock	3,700	$30.2558	$112K
Exercise	Common Stock	18,000	$8.05	$145K
Sale	Common Stock	18,000	$30.2558	$545K
Sale	Common Stock	19,200	$30.2557	$581K
Exercise	Stock Option (Right to Buy)	3,700	$0.00	--
Exercise	Common Stock	3,700	$2.59	$10K
Sale	Common Stock	3,700	$30.0758	$111K
Sale	Common Stock	3,700	$30.062	$111K

Holdings After Transaction: Stock Option (Right to Buy) — 9,072 shares (Direct, null); Common Stock — 60,150 shares (Direct, null); Common Stock — 133,969 shares (Indirect, By GrayMatters Consulting BV)

Footnotes (1)

1. This is a scheduled exercise and sale from 10b5-1 trading plan. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $30.00 to $30.20. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. This is a scheduled sale from 10b5-1 trading plan. GrayMatters Consulting B.V., an entity controlled by Dr. Lesage The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $30.00 to $30.75. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. 25% of the option vested on January 1, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter. 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.

Key Figures

Shares sold: 48,300 shares Options exercised: 25,400 shares Sale price example: $30.2557/share +4 more

7 metrics

Shares sold 48,300 shares Total Pharvaris common shares sold in open-market transactions

Options exercised 25,400 shares Total shares acquired via stock option exercises

Sale price example $30.2557/share Weighted-average sale price for 19,200-share transaction on April 30, 2026

Direct holdings after trades 56,450 shares Pharvaris common shares held directly following transactions

Indirect holdings after trades 133,969 shares Common shares held indirectly via GrayMatters Consulting B.V.

Remaining options at $8.05 82,000 options Stock options with $8.05 exercise price expiring in 2033

Remaining options at $2.59 9,072 options Stock options with $2.59 exercise price expiring in 2030

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, Stock Option (Right to Buy), restricted stock units, +1 more

5 terms

Rule 10b5-1 trading plan financial

"The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan."

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)" for derivative transactions exercising into common stock."

restricted stock units financial

"The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

indirect ownership financial

"direct_or_indirect: "I" and nature_of_ownership: "By GrayMatters Consulting BV" indicate indirect ownership of common stock."

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lesage Anne

(Last) (First) (Middle)

1 CRANBERRY HILL SUITE 400

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pharvaris N.V. [ PHVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Early Development

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/29/2026		M(1)		3,700	A	$2.59	60,150	D
Common Stock	04/29/2026		S(1)		3,700	D	$30.0758(2)	56,450	D
Common Stock	04/30/2026		M(1)		3,700	A	$2.59	60,150	D
Common Stock	04/30/2026		S(1)		3,700	D	$30.2558	56,450	D
Common Stock	04/30/2026		M(1)		18,000	A	$8.05	74,450	D
Common Stock	04/30/2026		S(1)		18,000	D	$30.2558	56,450	D
Common Stock	04/29/2026		S(3)		3,700	D	$30.062(2)	153,169	I	By GrayMatters Consulting BV(4)
Common Stock	04/30/2026		S(3)		19,200	D	$30.2557(5)	133,969	I	By GrayMatters Consulting BV(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.59	04/29/2026		M(1)			3,700	(6)	01/01/2030	Common Stock	3,700	$0	12,772	D
Stock Option (Right to Buy)	$2.59	04/30/2026		M(1)			3,700	(6)	01/01/2030	Common Stock	3,700	$0	9,072	D
Stock Option (Right to Buy)	$8.05	04/30/2026		M(1)			18,000	(7)	04/06/2033	Common Stock	18,000	$0	82,000	D

Explanation of Responses:

1. This is a scheduled exercise and sale from 10b5-1 trading plan.

2. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $30.00 to $30.20. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

3. This is a scheduled sale from 10b5-1 trading plan.

4. GrayMatters Consulting B.V., an entity controlled by Dr. Lesage

5. The reported price represents a weighted average sale price for shares sold in multiple transactions on the reported date pursuant to a Rule 10b5-1 trading plan. The shares reported herein include shares of common stock acquired upon vesting of restricted stock units on various dates. The sales prices for the transactions ranged from $30.00 to $30.75. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

6. 25% of the option vested on January 1, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter.

7. 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter.

	/s/ Marnus Nel, Attorney-in-Fact for Anne Lesage	05/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Pharvaris (PHVS) executive Anne Lesage report in this Form 4?

Anne Lesage reported exercising Pharvaris stock options and selling common shares. She exercised 25,400 shares at strike prices of $8.05 and $2.59 and sold 48,300 shares in open-market transactions executed under a pre-arranged Rule 10b5-1 trading plan.

How many Pharvaris (PHVS) shares did Anne Lesage sell, and at what prices?

Lesage sold a total of 48,300 Pharvaris common shares. Individual transactions show weighted-average sale prices around $30 per share, including prices such as $30.2557, $30.2558, $30.0758, and $30.0620, all executed pursuant to a Rule 10b5-1 trading plan.

What stock options did Anne Lesage exercise in Pharvaris (PHVS)?

She exercised options covering 25,400 Pharvaris common shares. These consisted of grants with exercise prices of $8.05 and $2.59 per share, with vesting schedules where 25% vested on specific dates and the remainder vests in monthly installments over 48 months.

How many Pharvaris (PHVS) shares does Anne Lesage hold after these transactions?

After the reported transactions, Lesage holds 56,450 Pharvaris common shares directly. She also has an indirect holding of 133,969 shares through GrayMatters Consulting B.V., an entity she controls, according to the ownership details disclosed in the filing.

Were the Pharvaris (PHVS) share sales by Anne Lesage pre-planned?

Yes. Footnotes state the sales were executed pursuant to a Rule 10b5-1 trading plan. These plans are pre-arranged trading instructions, meaning the timing and size of transactions were scheduled in advance rather than decided at the time of each trade.

What Pharvaris (PHVS) stock options does Anne Lesage still hold?

Post-transaction, the filing shows remaining options for 82,000 shares with an $8.05 exercise price expiring in 2033 and 9,072 options with a $2.59 exercise price expiring in 2030, reflecting continuing equity-based compensation exposure to Pharvaris.